MDGH-MOX-3001: Safety and efficacy of annual or biannual doses of moxidectin or ivermectin for onchocerciasis (Target: approx. 1,000 participants).
Follow our work by signing up for our newsletter
MDGH respectfully acknowledges the Traditional Owners of the land on which our office is located, the Wurundjeri people of the Kulin Nation, and pay our respect to their Elders past, present and emerging.
| Website by